At 7.7% CAGR, South & Central America Fill Finish Manufacturing Market is Projected to be Worth US$ 731.41 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the South & Central America fill finish manufacturing market was valued at US$ 403.07 million in 2022 and is expected to reach US$ 731.41 million by 2030, registering a CAGR of 7.7% from 2022 to 2030. Single-Use systems for aseptic fill finish and elevating demand for biologics are among the critical factors attributed to the South & Central America fill finish manufacturing market expansion.

Single-use disposable systems (SUDS) and single-use systems (SUS) for aseptic fill finish save time for pharmaceutical manufacturers, thereby allowing them to streamline their operations and shorten project schedules. Incorporating SUDS also helps them ensure regulatory compliance as well as confer environmental, health, and safety (EHS) benefits and facility design advantages. Furthermore, SUS accelerates the change over fill finish operations by simplifying end-of-batch breakdown and decontamination operations; the simplification of decontamination operations involves the elimination of time-consuming cleaning and preparation steps. The SUS is now being used in fill-finish operations. Bulk biotech operations have successfully deployed single-use systems for buffer and media preparations. They are currently implementing new single-use technologies such as fermentation and chromatography systems. Recent advancements in technology are making SUDS increasingly attractive for aseptic operations. For instance, a single-use line is a perfect fit for parenteral solution products with relatively low batch sizes (50-500L) that a peristaltic pump can transfer. Thus, rise in use of single use system for aseptic fill finish manufacturing will provide future trends in near future.

On the contrary, growing competition in biopharmaceutical contract manufacturing industry hurdles the growth of South & Central America fill finish manufacturing market.

Based on product, the South & Central America fill finish manufacturing market is bifurcated into consumables and instruments. The consumables segment held 57.8% share of South & Central America fill finish manufacturing market in 2022, amassing US$ 232.80 million. It is projected to garner US$ 433.18 million by 2030 to expand at 8.1% CAGR during 2022-2030. Furthermore, the consumables is sub segmented into prefilled syringes, glass vial/plastic vials, cartridges, and others.

In terms of modality, the South & Central America fill finish manufacturing market is categorized into recombinant proteins, monoclonal antibodies, vaccines, cell therapies and biological therapies, gene therapies, and others. The vaccines segment held 32.9% share of South & Central America fill finish manufacturing market in 2022, amassing US$ 132.52 million. It is projected to garner US$ 248.25 million by 2030 to expand at 8.2% CAGR during 2022-2030.

By end user, the South & Central America fill finish manufacturing market is segmented into contract manufacturing organizations, biopharmaceutical companies, and others. The contract manufacturing organizations segment held 47.9% share of South & Central America fill finish manufacturing market in 2022, amassing US$ 193.22 million. It is projected to garner US$ 357.81 million by 2030 to expand at 8.0% CAGR during 2022-2030.

Based on country, the South & Central America fill finish manufacturing market has been categorized into Brazil, Argentina, and the Rest of South & Central America. Our regional analysis states that Brazil captured 65.3% share of South & Central America fill finish manufacturing market in 2022. It was assessed at US$ 263.28 million in 2022 and is likely to hit US$ 490.36 million by 2030, exhibiting a CAGR of 8.1% during 2022-2030.

Key players operating in the South & Central America fill finish manufacturing market are Becton Dickinson and Co, Gerresheimer AG, IMA Industria Macchine Automatiche SpA, Maquinaria Industrial Dara SL, Nipro Medical Europe NV, Optima Packaging Group Gmbh, Schott AG, SGD SA, Stevanato Group SpA, Syntegon Technology GmbH, and West Pharmaceutical Services Inc, among others.

• In March 2023, Stevanato collaborates with Recipharm to develop and manufacture pre-fillable syringes for use in a new soft mist inhaler for the inhalation of sensitive biological products. This new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm's proprietary soft mist inhalers.
  
  
• In April 2023, isolated FLT is part of Versynta product line dedicated to small batch fill-finish. It is easy to operate for clinical or small commercial batches of drug product, with vial filling, stoppering, and capping processes all within a compact footprint.
  
  

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com